Mather Group’s United Therapeutics UTHR Stock Holding History

Mather Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8	Closed	-$1.76K	–	2278
2024 Q1	$1.76K	Buy	+8	New	+$1.8K	﹤0.01%	1565

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mather Group's UTHR Position: Q2 2024 in Review

Mather Group sold out of United Therapeutics (UTHR) in Q2 2024, closing a stake of 8 shares — an estimated $1.76K sold.

Mather Group first reported a position in UTHR in Q1 2024 and held it in 1 quarter. The position peaked at $1.76K in Q1 2024. 566 funds tracked by Wall St. Rank hold UTHR as of Q2 2024.

Mather Group reported no remaining United Therapeutics position as of Q2 2024 after selling out during the quarter.
Mather Group sold 8 United Therapeutics shares in Q2 2024, an estimated $1.76K.
Mather Group first reported a position in United Therapeutics in Q1 2024 and held it in 1 quarter.
Mather Group's United Therapeutics position peaked at $1.76K in Q1 2024.
566 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2024.

Based on Mather Group's 13F filing for Q2 2024, filed 9 Jul 2024.